메뉴 건너뛰기




Volumn 22, Issue 10, 2013, Pages 1329-1336

IMA901: A peptide vaccine in renal cell carcinoma

Author keywords

Cancer vaccine; IMA901; Immunotherapy; Peptide; Renal cell carcinoma

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; PEPTIDE VACCINE; SUNITINIB; UNCLASSIFIED DRUG;

EID: 84884268998     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.822066     Document Type: Article
Times cited : (11)

References (50)
  • 2
    • 84862874665 scopus 로고    scopus 로고
    • Second-line systemic therapy for the treatment of metastatic renal cell cancer
    • Kruck S, Bedke J, Kuczyk MA, et al. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2012;12:777-85
    • (2012) Expert Rev Anticancer Ther , vol.12 , pp. 777-785
    • Kruck, S.1    Bedke, J.2    Kuczyk, M.A.3
  • 3
    • 21044442672 scopus 로고    scopus 로고
    • Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
    • Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21
    • (2005) Clin Cancer Res , vol.11 , pp. 3714-3721
    • Atkins, M.1    Regan, M.2    McDermott, D.3
  • 4
    • 84893663818 scopus 로고    scopus 로고
    • Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy
    • published online 12 February 2013 doi: 10.1007/s00345-013-1033-3
    • Bedke J, Gouttefangeas C, Singh-Jasuja H, et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2013;published online 12 February 2013; doi: 10.1007/s00345-013- 1033-3
    • (2013) World J Urol
    • Bedke, J.1    Gouttefangeas, C.2    Singh-Jasuja, H.3
  • 5
    • 1542327748 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
    • Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6
    • (2004) J Urol , vol.171 , pp. 1071-1076
    • Flanigan, R.C.1    Mickisch, G.2    Sylvester, R.3
  • 6
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 7
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 8
    • 0027399243 scopus 로고
    • Peptides naturally presented by MHC class i molecules
    • Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44
    • (1993) Annu Rev Immunol , vol.11 , pp. 213-244
    • Rammensee, H.G.1    Falk, K.2    Rotzschke, O.3
  • 9
    • 0037108856 scopus 로고    scopus 로고
    • Integrated functional genomics approach for the design of patient-individual antitumor vaccines
    • Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002;62:5818-27
    • (2002) Cancer Res , vol.62 , pp. 5818-5827
    • Weinschenk, T.1    Gouttefangeas, C.2    Schirle, M.3
  • 10
    • 79959568681 scopus 로고    scopus 로고
    • Vaccination therapy in renal cell carcinoma: Current position and future options in metastatic and localized disease
    • Brookman-May S, Burger M, Wieland WF, et al. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines 2011;10:837-52
    • (2011) Expert Rev Vaccines , vol.10 , pp. 837-852
    • Brookman-May, S.1    Burger, M.2    Wieland, W.F.3
  • 11
    • 33745247366 scopus 로고    scopus 로고
    • Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
    • Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-18
    • (2006) Cancer Res , vol.66 , pp. 5910-5918
    • Wierecky, J.1    Muller, M.R.2    Wirths, S.3
  • 12
    • 84859101225 scopus 로고    scopus 로고
    • Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited
    • Randazzo M, Terness P, Opelz G, et al. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012;130:2219-31
    • (2012) Int J Cancer , vol.130 , pp. 2219-2231
    • Randazzo, M.1    Terness, P.2    Opelz, G.3
  • 13
    • 78651292217 scopus 로고    scopus 로고
    • Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations
    • Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39:D913-19
    • (2011) Nucleic Acids Res , vol.39
    • Gonzalez-Galarza, F.F.1    Christmas, S.2    Middleton, D.3
  • 14
    • 84864662070 scopus 로고    scopus 로고
    • Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
    • published online 29 July 2012 doi:10.1038/nm.2883
    • Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;published online 29 July 2012; doi:10.1038/nm.2883
    • (2012) Nat Med
    • Walter, S.1    Weinschenk, T.2    Stenzl, A.3
  • 15
    • 0028326159 scopus 로고
    • Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
    • Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-9
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 2105-2109
    • Celis, E.1    Tsai, V.2    Crimi, C.3
  • 16
    • 1542267730 scopus 로고    scopus 로고
    • The Tubingen approach: Identification, selection, and validation of tumor-associated HLA peptides for cancer therapy
    • Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004;53:187-95
    • (2004) Cancer Immunol Immunother , vol.53 , pp. 187-195
    • Singh-Jasuja, H.1    Emmerich, N.P.2    Rammensee, H.G.3
  • 17
    • 80053343071 scopus 로고    scopus 로고
    • Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
    • Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 2011;17:325-30
    • (2011) Cancer J , vol.17 , pp. 325-330
    • Seremet, T.1    Brasseur, F.2    Coulie, P.G.3
  • 18
    • 0026322151 scopus 로고
    • A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    • van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7
    • (1991) Science , vol.254 , pp. 1643-1647
    • Van Der Bruggen, P.1    Traversari, C.2    Chomez, P.3
  • 19
    • 2542526311 scopus 로고    scopus 로고
    • Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes
    • Schag K, Schmidt SM, Muller MR, et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004;10:3658-66
    • (2004) Clin Cancer Res , vol.10 , pp. 3658-3666
    • Schag, K.1    Schmidt, S.M.2    Muller, M.R.3
  • 20
    • 10744230512 scopus 로고    scopus 로고
    • Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis
    • Schmidt SM, Schag K, Muller MR, et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004;64:1164-70
    • (2004) Cancer Res , vol.64 , pp. 1164-1170
    • Schmidt, S.M.1    Schag, K.2    Muller, M.R.3
  • 21
    • 79954458103 scopus 로고    scopus 로고
    • Immunological perspective of self versus tumor antigens: Insights from the RIP-gp model
    • Dissanayake D, Gronski MA, Lin A, et al. Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. Immunol Rev 2011;241:164-79
    • (2011) Immunol Rev , vol.241 , pp. 164-179
    • Dissanayake, D.1    Gronski, M.A.2    Lin, A.3
  • 22
    • 14944360112 scopus 로고    scopus 로고
    • Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
    • Probst HC, McCoy K, Okazaki T, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6:280-6
    • (2005) Nat Immunol , vol.6 , pp. 280-286
    • Probst, H.C.1    McCoy, K.2    Okazaki, T.3
  • 23
    • 84877940678 scopus 로고    scopus 로고
    • Trial watch: Peptide vaccines in cancer therapy
    • Vacchelli E, Martins I, Eggermont A, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012;1:1557-76
    • (2012) Oncoimmunology , vol.1 , pp. 1557-1576
    • Vacchelli, E.1    Martins, I.2    Eggermont, A.3
  • 25
    • 1642578298 scopus 로고    scopus 로고
    • Dr William Coley and tumour regression: A place in history or in the future
    • Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003;79:672-80
    • (2003) Postgrad Med J , vol.79 , pp. 672-680
    • Hoption Cann, S.A.1    Van Netten, J.P.2    Van Netten, C.3
  • 26
    • 84855172987 scopus 로고    scopus 로고
    • Toll-like receptor 4 activation in cancer progression and therapy
    • Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011;2011:609579
    • (2011) Clin Dev Immunol , vol.2011 , pp. 609579
    • Oblak, A.1    Jerala, R.2
  • 27
    • 33847258205 scopus 로고    scopus 로고
    • Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
    • Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-32
    • (2007) Ann Oncol , vol.18 , pp. 226-232
    • Parmiani, G.1    Castelli, C.2    Pilla, L.3
  • 28
    • 15944410592 scopus 로고    scopus 로고
    • Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
    • Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
    • (2005) Blood , vol.105 , pp. 2862-2868
    • Lutsiak, M.E.1    Semnani, R.T.2    De Pascalis, R.3
  • 29
    • 33750704266 scopus 로고    scopus 로고
    • Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide
    • Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide. Oncol Rep 2006;16:141-6
    • (2006) Oncol Rep , vol.16 , pp. 141-146
    • Motoyoshi, Y.1    Kaminoda, K.2    Saitoh, O.3
  • 31
    • 47049127786 scopus 로고    scopus 로고
    • Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
    • Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20
    • (2008) Blood , vol.111 , pp. 5610-5620
    • Hipp, M.M.1    Hilf, N.2    Walter, S.3
  • 34
    • 0033198562 scopus 로고    scopus 로고
    • The makings of a tumor rejection antigen
    • Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70
    • (1999) Immunity , vol.11 , pp. 263-270
    • Gilboa, E.1
  • 35
    • 0033556322 scopus 로고    scopus 로고
    • High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
    • Zeh HJ III, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94
    • (1999) J Immunol , vol.162 , pp. 989-994
    • Zeh, H.J.1    Perry-Lalley, D.2    Dudley, M.E.3
  • 36
    • 84871503916 scopus 로고    scopus 로고
    • Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
    • Bedke J, Laske K, Feyerabend S, et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol Suppl 2012;11:e76-ea
    • (2012) Eur Urol Suppl , vol.11
    • Bedke, J.1    Laske, K.2    Feyerabend, S.3
  • 37
    • 34547720636 scopus 로고    scopus 로고
    • Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas
    • Dengjel J, Nastke MD, Gouttefangeas C, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006;12:4163-70
    • (2006) Clin Cancer Res , vol.12 , pp. 4163-4170
    • Dengjel, J.1    Nastke, M.D.2    Gouttefangeas, C.3
  • 38
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3
  • 39
    • 0034047619 scopus 로고    scopus 로고
    • Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colonystimulating factor or Flt3-ligand
    • Mach N, Gillessen S, Wilson SB, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colonystimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-46
    • (2000) Cancer Res , vol.60 , pp. 3239-3246
    • Mach, N.1    Gillessen, S.2    Wilson, S.B.3
  • 40
    • 0031570843 scopus 로고    scopus 로고
    • Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells
    • Qin Z, Noffz G, Mohaupt M, et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells. J Immunol 1997;159:770-6
    • (1997) J Immunol , vol.159 , pp. 770-776
    • Qin, Z.1    Noffz, G.2    Mohaupt, M.3
  • 41
    • 0029833732 scopus 로고    scopus 로고
    • Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
    • Young MR, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996;67:333-8
    • (1996) Int J Cancer , vol.67 , pp. 333-338
    • Young, M.R.1    Wright, M.A.2    Lozano, Y.3
  • 42
    • 0031570886 scopus 로고    scopus 로고
    • Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas
    • Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 1997;159:990-6
    • (1997) J Immunol , vol.159 , pp. 990-996
    • Young, M.R.1    Wright, M.A.2    Pandit, R.3
  • 43
    • 4344590947 scopus 로고    scopus 로고
    • High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
    • Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43
    • (2004) Cancer Res , vol.64 , pp. 6337-6343
    • Serafini, P.1    Carbley, R.2    Noonan, K.A.3
  • 44
    • 0030944023 scopus 로고    scopus 로고
    • Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
    • Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46
    • (1997) Cancer Res , vol.57 , pp. 1537-1546
    • Simons, J.W.1    Jaffee, E.M.2    Weber, C.E.3
  • 45
    • 0033998594 scopus 로고    scopus 로고
    • Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor
    • Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor. J Clin Oncol 2000;18:1614-21
    • (2000) J Clin Oncol , vol.18 , pp. 1614-1621
    • Spitler, L.E.1    Grossbard, M.L.2    Ernstoff, M.S.3
  • 46
    • 67049156789 scopus 로고    scopus 로고
    • Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
    • Feyerabend S, Stevanovic S, Gouttefangeas C, et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917-27
    • (2009) Prostate , vol.69 , pp. 917-927
    • Feyerabend, S.1    Stevanovic, S.2    Gouttefangeas, C.3
  • 47
    • 58149179532 scopus 로고    scopus 로고
    • Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    • Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
    • (2008) Clin Cancer Res , vol.14 , pp. 6674-6682
    • Finke, J.H.1    Rini, B.2    Ireland, J.3
  • 48
    • 58149332680 scopus 로고    scopus 로고
    • Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    • Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008;14:8270-8
    • (2008) Clin Cancer Res , vol.14 , pp. 8270-8278
    • Kusmartsev, S.1    Su, Z.2    Heiser, A.3
  • 50
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'day, S.J.2    McDermott, D.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.